Genetic code

Optum Launches Laboratory Benefit Management Solution to Reduce Unnecessary Testing and Improve Quality of Care

Retrieved on: 
Wednesday, June 22, 2022
Data Management, Practice Management, Technology, Managed Care, Other Health, Health, General Health, Other Technology, Health Insurance, Software, Hospitals, National library, Patient, Internal medicine, Population, UNH, Genetic code, Christopher St. John, Prevalence, Meta-analysis, Anatomy, MD, Mark (given name), United States National Library of Medicine, PMID, UnitedHealth Group, NYSE, PLOS One, Pharmaceutical industry, Medical device, Optum

Optum today announced the launch of a comprehensive laboratory benefit management solution designed to help health plans reduce unnecessary lab testing and ensure their members receive appropriate, high-quality tests.

Key Points: 
  • Optum today announced the launch of a comprehensive laboratory benefit management solution designed to help health plans reduce unnecessary lab testing and ensure their members receive appropriate, high-quality tests.
  • The offering will help health plans align lab testing with clinical, evidence-based guidelines and automate large parts of lab benefit administration.
  • This new solution will help health plans determine which tests are clinically proven, streamline decisions and automate processes to significantly reduce unnecessary testing for their members and increase cost savings.
  • This laboratory benefit management solution leverages deep clinical expertise to help guide clinicians to the tests with the highest clinical validity and utility.

PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy

Retrieved on: 
Monday, June 20, 2022
Heart, Review, PTC Therapeutics, Lists of diseases, Genetic code, Death, LinkedIn, European Economic Area, Ageing, Dystrophin, Muscle, NASDAQ, PTC, Diaphragm, Twitter, Patient, Duchenne muscular dystrophy, Muscle weakness, Therapy, Pharmaceutical industry, Duchenne, Facebook

to review topline results from Study 041 of Translarna (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy.

Key Points: 
  • to review topline results from Study 041 of Translarna (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy.
  • A live, listen-only webcast can be accessed on the Events and Presentations page under the investor relations section ofPTC Therapeutics'website at www.ptcbio.com .
  • A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein.
  • Translarna, the tradename of ataluren, is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged two years and older.

Vivera Appoints Dr. Fabio Macciardi as Neurogenetics Scientific Advisor

Retrieved on: 
Thursday, June 16, 2022
RNA, CNS, Drug development, Schizophrenia, CEO, Eli Lilly and Company, University of California, Irvine Medical Center, School, Genetic code, Gene expression, Company, Brain, Medical school, Autism, Research, Neuroscience, Advisory board, DNA, Central nervous system, Tongue, University, Neurogenesis, Lists of diseases, Alzheimer's disease, Telehealth, Patient, UCI, TES, Medical device, Vaccine, Pharmaceutical industry

NEWPORT BEACH, Calif., June 16, 2022 /PRNewswire/ -- Vivera Pharmaceuticals is pleased to welcome Fabio Macciardi, M.D., Ph.D., to its Advisory Board as Neurogenetics Scientific Advisor to the Company's Biosciences Division .

Key Points: 
  • NEWPORT BEACH, Calif., June 16, 2022 /PRNewswire/ -- Vivera Pharmaceuticals is pleased to welcome Fabio Macciardi, M.D., Ph.D., to its Advisory Board as Neurogenetics Scientific Advisor to the Company's Biosciences Division .
  • -Paul Edalat
    "I am looking forward to joining Vivera as we utilize our knowledge of the human brain to develop therapeutic tools for patients with neuropsychiatric disorders," said Dr. Macciardi.
  • "We are honored to welcome Dr. Macciardi to Vivera's Advisory Board," said Paul Edalat, Chairman and CEO of Vivera.
  • Utilizing his scientific background, Dr. Macciardi will help Vivera select medications that may better serve patients in a sublingual format.

Leveraging Patent Intelligence and Network Analysis to Quantify Technology Influence in CRISPR, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, June 7, 2022
Industry, Eye, Genetic code, Clusters of Innovation, Technology, DNA, Research, Agriculture, Invention, Food, Risk management, Pharmaceutical industry, CRISPR

TORONTO, June 7, 2022 /PRNewswire-PRWeb/ -- CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) as a technology is akin to a pair of gene scissors that can target and cut a DNA sequence. This revolutionary gene editing method allows scientists to rewrite the genetic code in almost any organism, while being cheaper, simpler and more precise than any of its gene-editing predecessors. Unsurprisingly, interest in this field is increasing at an exponential rate. New innovations in agriculture, treatments of debilitating illnesses, and genetic prevention of inherited illness are all being explored in detail.

Key Points: 
  • In this free webinar, learn about leveraging patent intelligence and network analysis to quantify technology influence in CRISPR.
  • The featured speaker will introduce network analysis and speak about leveraging patents as an indicator of relationships between businesses.
  • Join this webinar to learn more about leveraging patent intelligence and network analysis to quantify technology influence in CRISPR.
  • For more information, or to register for this event, visit Leveraging Patent Intelligence and Network Analysis to Quantify Technology Influence in CRISPR.

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Retrieved on: 
Thursday, May 26, 2022
Lists of diseases, DNA, Babraham Institute, Genome, Company, Disease, Research, Coronary heart disease, susceptibility to, 8, Multiomics, Challenge, Science, VC, Patient, Solution, Health, UK Research and Innovation, Thane, Institute, BBSRC, Neurodegeneration, Mentorship, Industry, Genetic code, Life, Genomics, Biomarker, Technology, Biotechnology, Biotechnology and Biological Sciences Research Council, Maintenance, Precision medicine, Biology, 3D, Family, Innovation, Pharmaceutical industry, Antibiotics, Financial services, Medical imaging, EU

CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .

Key Points: 
  • CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .
  • Debora Lucarelli, Chief Executive Officer of Enhanc3D Genomics, commented: "Our vision is to leverage the human 3D genome and state-of-the-art analytics of our platform GenLink3DTMto enable breakthroughs in precision medicine.
  • We invested in Enhanc3D with a strong belief that GenLink3DTM will revolutionise patient centric medicine as a first-in-class 3D genomics navigator.
  • ENHANC3D GENOMICS ("Enhanc3D") is a private functional genomics company based in Cambridge, UK which was founded in 2020 out of Professor Peter Fraser's pioneering 3D genome organisation research laboratory at the Babraham Institute.

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Retrieved on: 
Thursday, May 26, 2022
Lists of diseases, DNA, Babraham Institute, Genome, Company, Disease, Research, Coronary heart disease, susceptibility to, 8, Multiomics, Challenge, Science, VC, Patient, Solution, Health, UK Research and Innovation, Thane, Institute, BBSRC, Neurodegeneration, Mentorship, Industry, Genetic code, Life, Genomics, Biomarker, Technology, Biotechnology, Biotechnology and Biological Sciences Research Council, Maintenance, Precision medicine, Biology, 3D, Family, Innovation, Pharmaceutical industry, Antibiotics, Financial services, Medical imaging, EU

CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .

Key Points: 
  • CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .
  • Debora Lucarelli, Chief Executive Officer of Enhanc3D Genomics, commented: "Our vision is to leverage the human 3D genome and state-of-the-art analytics of our platform GenLink3DTMto enable breakthroughs in precision medicine.
  • We invested in Enhanc3D with a strong belief that GenLink3DTM will revolutionise patient centric medicine as a first-in-class 3D genomics navigator.
  • ENHANC3D GENOMICS ("Enhanc3D") is a private functional genomics company based in Cambridge, UK which was founded in 2020 out of Professor Peter Fraser's pioneering 3D genome organisation research laboratory at the Babraham Institute.

Cortexyme Announces Agreement to Acquire Novosteo

Retrieved on: 
Tuesday, May 10, 2022
Research, Infectious Diseases, Dental, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Board, Bone, U.S. Securities and Exchange Commission, Investment, Bone fracture, Forward-looking statement, Board of directors, IND, Nasdaq, Twitter, Birth, Osteogenesis imperfecta, Collagen, Director, Safety, Time, Patient, Doctor of Philosophy, Security (finance), Review, Degenerative disease, Wilson Sonsini Goodrich & Rosati, FDA, Periodontal disease, Cooley LLP, Therapy, Genetic code, Leadership, Osteoblast, CMO, Bone disease, SEC, CEO, News, Growth, Acquisition, Pharmaceutical industry, Management, Medical imaging

Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company.

Key Points: 
  • Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company.
  • We intend to capitalize on the combined assets of Novosteo and Cortexyme by driving our therapeutic candidates through development, expanding our targeted drug discovery platform, and pursuing new business development opportunities.
  • Cooley LLP acted as legal advisor to Cortexyme and Wilson Sonsini Goodrich & Rosati acted as legal advisor to Novosteo.
  • To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Monday, May 2, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Genetics, Forward-looking statement, Outline, Nasdaq, Factor X, CNS, Institutional review board, Cell, AAV, Patient, Gene, Annual report, Genetic code, U.S. Securities and Exchange Commission, 2021 Essex County Council election, Society, Traffic barrier, Technology, Research, Central nervous system, Therapy, Pharmaceutical industry, Vaccine, Powder metallurgy, Wood drying, Sangamo Therapeutics

Presentations will focus on the progression of Sangamos pre-clinical programs emerging from its genomic engineering platform.

Key Points: 
  • Presentations will focus on the progression of Sangamos pre-clinical programs emerging from its genomic engineering platform.
  • With protection from the blood-brain barrier, current gene delivery to the CNS continues to be an obstacle.
  • Sangamos AAV capsids are designed to overcome that barrier, providing broad CNS access while minimizing exposure to a patients pre-existing anti-AAV antibodies.
  • Sangamo will also present data from its CAR-Treg cell therapy platform, including outlining advancements in pre-clinical allogeneic Treg engineering.

Cambridge Innovation Capital Raises £225 million ($300 million) Fund II

Retrieved on: 
Monday, April 25, 2022
Pragmatism, CMR Surgical, Financial Conduct Authority, Robotics, CIC, Twitter, List, Genomics, Liquid biopsy, Patient, Artificial intelligence, LinkedIn, Electronics, Technology, Genetic code, Investment, Semiconductor, University, Silicon, Therapy, Cancer, Fine chemical, Fund

Cambridge, UK: April 25, 2022 - Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses connected with the Cambridge ecosystem, has raised 225 million ($300 million) for its oversubscribed second fund (Fund II).

Key Points: 
  • Cambridge, UK: April 25, 2022 - Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses connected with the Cambridge ecosystem, has raised 225 million ($300 million) for its oversubscribed second fund (Fund II).
  • Andrew Williamson, Managing Partner of CIC, commented: Cambridge, UK is one of the fastest-growing science and technology innovation ecosystems in the world.
  • With Fund II, CIC now manages in excess of 500 million, giving it the scale to support its portfolio companies throughout their life cycle, providing investment capital as well as strategic and operational support.
  • Cambridge Innovation Capital (CIC) is a leading venture investor backing and building category-leading deep tech and life sciences companies.

Cincinnati Children's and CTI Announce Name and Managing Director of Joint Venture

Retrieved on: 
Tuesday, April 19, 2022
Genetic code, Gene, CEO, Cincinnati Children's Hospital Medical Center, ISCT, Biotechnology, Medicine, Neurology, Clinical trial, Degenerative disease, Research, Good, Good manufacturing practice, MD, Leadership, GMP, News, Hospital, Education, Doctor of Philosophy, National, U.S. News & World Report, Executive Committee, Patient, Nephrology, Consultant, Growth, Infection, Regenerative medicine, International Society, MEA, Transplant, Disease, PCT, Child, CTI, Health, Cell, Pharmaceutical industry, Management, Vaccine, Cincinnati metropolitan area

"I've been working in the world of cell and gene therapy for decades, and I'm looking forward to bringing the lessons I've learned from previous experiences to this joint venture," Preti said.

Key Points: 
  • "I've been working in the world of cell and gene therapy for decades, and I'm looking forward to bringing the lessons I've learned from previous experiences to this joint venture," Preti said.
  • "It also will support Cincinnati Children's efforts as one of the leading medical centers committed to scientific research, training and education."
  • CTI and Cincinnati Children's agreed in December 2021 to form the joint venture , noting that medicine is rapidly evolving toward cell- and gene-based therapies.
  • CTI is headquartered in the Greater Cincinnati area, with operations across North America, Europe, Latin America, MEA and Asia-Pacific.